Iovance Biotherapeutics, Inc. (IOVA) stock soared 5.31% in the pre-market session on Monday, following positive analyst coverage from Chardan Capital and Truist Financial.
Chardan Capital reiterated its "Buy" rating on the biopharmaceutical company, while Truist Financial also maintained a "Buy" rating on IOVA shares. The analysts' positive outlook on the company's prospects appears to have fueled investor confidence, driving the stock's significant pre-market gain.
Despite the lack of specific details regarding the analysts' rationale for their bullish stance, the market seems to have responded favorably to the reaffirmation of "Buy" ratings from these respected firms, suggesting optimism about Iovance Biotherapeutics' future growth and performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.